Advances in Management of Moderate to Severe Atopic Dermatitis in Children and Adolescents Evaluation (ID: i743a) Survey

Question Title

* 2. Following participation in this activity, please select which of the following items you will include in patient education plans in your current practice.

Written treatment plans

Recommendation to moisturize frequently

Information that topical medications do not take the place of moisturizers

Importance of adherence

Recommendation to continue maintenance treatments even when skin appears healthy

Question Title

* 3. After participating in today’s activity, I have improved knowledge of clinical data supporting use of new and emerging therapies for AD.

Strongly agree

Agree

Neutral

Disagree

Strongly disagree

Question Title

* 4. As a result of participating in this activity, will you change components of your communication with patients with AD? If so, please describe changes.

Question Title

* 5. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information that I can apply to my area of practice

I need more information before I change my practice behavior

This activity will not change my practice, as my current practice is consistent with theinformation presented

This activity will not change my practice, as I do not agree with the information presented

Question Title

* 6. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

Question Title

* 7. After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Accurately diagnose and assess severity of disease in children and adolescents with atopic dermatitis (AD)	Accurately diagnose and assess severity of disease in children and adolescents with atopic dermatitis (AD) Strongly agree	Accurately diagnose and assess severity of disease in children and adolescents with atopic dermatitis (AD) Agree	Accurately diagnose and assess severity of disease in children and adolescents with atopic dermatitis (AD) Neutral	Accurately diagnose and assess severity of disease in children and adolescents with atopic dermatitis (AD) Disagree	Accurately diagnose and assess severity of disease in children and adolescents with atopic dermatitis (AD) Strongly disagree
Utilize guidelines to design treatment plans for patients with AD based on disease severity	Utilize guidelines to design treatment plans for patients with AD based on disease severity Strongly agree	Utilize guidelines to design treatment plans for patients with AD based on disease severity Agree	Utilize guidelines to design treatment plans for patients with AD based on disease severity Neutral	Utilize guidelines to design treatment plans for patients with AD based on disease severity Disagree	Utilize guidelines to design treatment plans for patients with AD based on disease severity Strongly disagree
Identify patients with AD who are inadequately controlled on topical therapy and are candidates for treatment with biologic therapy	Identify patients with AD who are inadequately controlled on topical therapy and are candidates for treatment with biologic therapy Strongly agree	Identify patients with AD who are inadequately controlled on topical therapy and are candidates for treatment with biologic therapy Agree	Identify patients with AD who are inadequately controlled on topical therapy and are candidates for treatment with biologic therapy Neutral	Identify patients with AD who are inadequately controlled on topical therapy and are candidates for treatment with biologic therapy Disagree	Identify patients with AD who are inadequately controlled on topical therapy and are candidates for treatment with biologic therapy Strongly disagree
Discuss efficacy and safety of biologic therapies for the management of patients with AD and considerations for their use	Discuss efficacy and safety of biologic therapies for the management of patients with AD and considerations for their use Strongly agree	Discuss efficacy and safety of biologic therapies for the management of patients with AD and considerations for their use Agree	Discuss efficacy and safety of biologic therapies for the management of patients with AD and considerations for their use Neutral	Discuss efficacy and safety of biologic therapies for the management of patients with AD and considerations for their use Disagree	Discuss efficacy and safety of biologic therapies for the management of patients with AD and considerations for their use Strongly disagree

Question Title

* 8. Peter A. Lio, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 9. Peck Y. Ong, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 10. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 11. What barriers do you see to making changes in your practice?

Question Title

* 12. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities:

Question Title

* 13. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 14. How would you rate the format of this activity?

Excellent

Average

Below average

Poor

Question Title

* 15. Would you be willing to participate in a post activity follow-up survey?

Yes

Question Title

* 1. How many patients with AD do you manage in your practice?

Question Title

* 2. Following participation in this activity, please select which of the following items you will include in patient education plans in your current practice.

Question Title

* 3. After participating in today’s activity, I have improved knowledge of clinical data supporting use of new and emerging therapies for AD.

Question Title

* 4. As a result of participating in this activity, will you change components of your communication with patients with AD? If so, please describe changes.

Question Title

* 5. Which of the following best describes the impact of this activity on your performance?

Question Title

* 6. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 7. After participating in today’s activity, I am now able to:

Question Title

* 8. Peter A. Lio, MD, effectively:

Question Title

* 9. Peck Y. Ong, MD, effectively:

Question Title

* 10. The content presented:

Question Title

* 11. What barriers do you see to making changes in your practice?

Question Title

* 12. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities:

Question Title

* 13. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 14. How would you rate the format of this activity?

Question Title

* 15. Would you be willing to participate in a post activity follow-up survey?